myasthenia gravis ppt
TRANSCRIPT
-
8/13/2019 Myasthenia Gravis ppt
1/23
PATHOPHYSIOLOGY
-
8/13/2019 Myasthenia Gravis ppt
2/23
Age
Predisposing Factor
Incidence of Myasthenia Gravisoccurs between ages 15-35 for
women. (Porth p.1131)
Our patient is 29 years old.
Gender
HereditaryA person born into family withhistory of certain autoimmune
disease is at risk of developing
such autoimmune disease.(www.emedicine.com)
Myasthenia Gravis is three times
more common in women than men.(Porth, p1131)
-
8/13/2019 Myasthenia Gravis ppt
3/23
Precipitating Factor
Poor environmentPoor house/ office
Ventilationcrowded environment
Location
StressOccupation
Constant exposure to dustor chemical substances can
weaken the immune systemof every individual that
lead to infection.(www.emedicine.com)
Stress can weaken the immune system.According to psychoneuroimmunology, they
found consistent stress-related increases innumbers of total white blood cell, as well asdecreases in the numbers of helper T cells,suppressor T cells, and cytotoxic T cells, Bcell, and natural killer T cells.
(www.emedicine.com)
-
8/13/2019 Myasthenia Gravis ppt
4/23
Predisposing FactorPrecipitating Factor
Abnormal DNA mutation
Production of abnormalT-Cells
Difference in the variableRegion of antibodies
Decrease # of T-cell
Alteration of the T-cells function
-
8/13/2019 Myasthenia Gravis ppt
5/23
Abnormal Antibodies
Unable to recognize Self-antigen
Attacking the AcetylcholineReceptor Sites
Inhibit musclespecific Protein
MuSK
Malformations ofNeuromuscular
Junction
Destruction of AcetylcholineReceptor Sites
Decreased PatencyOf NeuromuscularJunction
Decrease # of functioningAcetylcholine Receptors site
-
8/13/2019 Myasthenia Gravis ppt
6/23
-
8/13/2019 Myasthenia Gravis ppt
7/23
Myasthenia Gravis
S/sxExpressionless faceNasal timbrePtosis
DiplopiaDysphagiaDysarthriaDysphoniaWeakness of all Extremities
-
8/13/2019 Myasthenia Gravis ppt
8/23
-
8/13/2019 Myasthenia Gravis ppt
9/23
A blood test for the remaining 15% of seronegative (SN) MG patients, thosewho have tested negative for the acetylcholine antibody, 40-70% testpositive for the anti-MuSK antibody. The remaining patients have anunidentified antibody causing their MG.
Anti-MuSK Antibody testing
Nursing DiagnosisFatigue r/t generalized muscle weakness 2 MG.
Independent Action:
Schedule/ organize activitiesAssist pt. with ADLs These can minimize energy expenditure and prevent injury with activities
-
8/13/2019 Myasthenia Gravis ppt
10/23
Collaborative:
Pyridostismine bromide 65mg/ tab, 1 tab t.i.d. Pyridostigmine is used to improve muscle strength in patients
with a certain muscle disease (myasthenia gravis). It works by
preventing the breakdown of a certain natural substance
(acetylcholine) in your body. Acetylcholine is needed for normal
muscle function.
Azathioprine 50mg tab O.D.
An immunosuppressive medication that decreases the actions of
the bodysimmune system. Drugs that suppress the immune system
are used in patients with myasthenia gravis because MG is an
autoimmune disorder that results from the production of abnormal
antibodies.
-
8/13/2019 Myasthenia Gravis ppt
11/23
Prednisone 20mg, 1 tab q 12
Prednisone is a corticosteroid hormone (glucocorticoid). It decreases your
immune system's response to various diseases to reduce symptoms such asswelling and allergic-type reactions. It is used to treat conditions such as
arthritis, blood disorders, breathing problems, certain cancers, eye problems,
immune system diseases, and skin diseases.
S/sx
Inability to expectoraterespiratory muscle weakness
Disruption of mechanical
defense
Invasion of microorganism innasal
-
8/13/2019 Myasthenia Gravis ppt
12/23
-
8/13/2019 Myasthenia Gravis ppt
13/23
S/Sx:CoughCrackles
Diagnostic Test
Jan. 5 - Increased WBC-Neutrophils- 90 x10g/lLymphocytes- 4x10g/l
Jan. 9- ETA/ GSCS result
14-16x10g/l
The culture result reveals that the specific type
of bacteria called Acinetobacter baumaanii issusceptible to certain types of antibiotics such as:
Amikacin, Ampi/Sulbactam, Ceftaxidine,
Ciprofloxacin, Gentamicin, Ticarcillin and Tobramycin;
hence, effective in killing these types of microorganisms.
-
8/13/2019 Myasthenia Gravis ppt
14/23
Nursing Diagnosis
Ineffective airway clearance r/t retainedtracheobronchial secretions 2 MG, CAP
Independent Action:
Suction secretion ,prn It mechanically clears airway in pt. who is unable
to do so because of ineffective cough.Assist pt. in performing Deep breathing exercises Deep breathing facilitates maximum expansionof the lung areas.
Collaborative
Sultamicilline 150mg, 1 tab. B.i.d.Acinetobacter baumaanii is susceptible toSultamicilline
-
8/13/2019 Myasthenia Gravis ppt
15/23
From MG
If treated:MedicationsLaboratoriesSurgeriesHealth Teachings
If treated
Activation of immune system
Release of Endotoxin andexotoxins
If complaint If not compliant Inflammation of the Lungsparenchyma
PNEUMONIAFurther distraction of
Acetylcholine Receptorsites
Lessen the S/sx
Colonization of microorganism
Invasion of microorganism in
the lungs
-
8/13/2019 Myasthenia Gravis ppt
16/23
-
8/13/2019 Myasthenia Gravis ppt
17/23
Nursing Diagnosis
Risk for Aspiration r/t muscle weakness 2 MG
Independent Action:
Assess Gag reflex Pt. with weak gag reflex is at risk for aspiration
Keep pt. upright for 30-60 min. after meals
The upright position facilitates the gravitational flow offood or fluid through the alimentary tract and reduces therisk of aspiration.
Keep suction equipment at bedside and suction necessary.
This is necessary to maintain patent airway.
Collaborative:Monitor ABG and pulse oximeter pulling of secretions leads to pneumonia which will lead tomore aggressive interventions.
-
8/13/2019 Myasthenia Gravis ppt
18/23
-
8/13/2019 Myasthenia Gravis ppt
19/23
From MG
If treated:MedicationsLaboratoriesSurgeriesHealth Teachings
If treated
Activation of immune system
Release of Endotoxin andexotoxins
If complaint If not compliant Inflammation of the Lungsparenchyma
PNEUMONIAFurther distraction of
Acetylcholine Receptorsites
Lessen the S/sx
Colonization of microorganism
Invasion of microorganism in
the lungs
-
8/13/2019 Myasthenia Gravis ppt
20/23
-
8/13/2019 Myasthenia Gravis ppt
21/23
Criteria Poor(1)
Fair
(2)
Good
(3)
Justification
a. Duration of illness Our patient has been diagnosed withMyasthenia Gravis for more than a yearnow. She has been admitted for a few
times due to the complications led by her
illness.
b. Onset of Illness During the first few weeks upon the onsetof symptoms, the patient continuedworking as a clerk. She only sought for
medical intervention when she can no
longer bear the symptoms she felt.
c. Precipitating
Factors With the precipitating factors, our patient
has poor prognosis since her age bracket
falls in middle adulthood (29 years old).
Considering also that she is a female and
such disease is common in their gender.
-
8/13/2019 Myasthenia Gravis ppt
22/23
d. Willingness to takeMedications
Our patient was able to comply with hermedications as evidenced by taking in her
medicine on time and having sufficient
financial resources to sustain her
medications.
e. Age Myasthenia Gravis commonly affects youngadult women, usually those under the age of
40. Since our patient is 29 years old, she has
a poor prognosis when age is considered.
f. Environment Our patient lives in a stressful environment.Stress can trigger the remission of
symptoms
g. Family Support The patientsfamily is supportive. They arealways there when she needs them.
Score: 2+2+1+3+1+1+3= 13/7=1.85 (poor - fair)
-
8/13/2019 Myasthenia Gravis ppt
23/23
Based on the data, our patient got an average score of
1.85 in 7 criteria which means poor to fair prognosis.
In addition, both fair and good prognosis got 2 criteria
while the precipitating factors, age, and environment got a score
of 1 or poor prognosis. With this data, our patient is more
susceptible for the recurrence of the disease. If this will not becorrected, this will lead to poor prognosis.
If the patient is compliant with the treatment, she will
have a significant improvement in her muscle weakness and
can expect to live a normal life. If some factors such as stress
Will be encountered then there is possible recurrence.